Heart Failure Preserved Ejection Fraction
14
5
6
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 14 trials
100.0%
+13.4% vs benchmark
14%
2 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (14)
Coronary Sinus Reducer For The Management Of Symptomatic Heart Failure
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
Exercise Testing After Preeclampsia
Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients
Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
Neuromuscular Fatigue and Exercise Capacity in Patients With Type 2 Diabetes Mellitus and HFpEF
Mechanistic Insights From Temporary Pacing in HFpEF
The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction
Middle-aged Women With Adverse Pregnancy Outcomes and Heart Failure With Preserved Ejection Fraction
Characterization of Heart Failure With Preserved Ejection Fraction
Relative Importance of Cardiovascular Risk Factors and Echocardiographic Parameters Affecting Left Atrial Strain
Resistance Training in HFpEF